Polish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Saw Palmetto: Symptom Management for Men During Radiation Therapy

Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły
Zaloguj się Zarejestruj się
Link zostanie zapisany w schowku
StatusZakończony
Sponsorzy
Michigan State University

Słowa kluczowe

Abstrakcyjny

The aim of this study is to test whether Saw Palmetto, is useful in preventing or reducing the side effects for men undergoing radiation therapy for prostate cancer. Urinary symptoms will be recorded each week, as well as assessment of quality of life through: 1) Physical Well-Being 2) Social/Family Well-being 3) Emotional Well-Being, and 4) Functional Well-Being.

Opis

Lower urinary tract symptoms (LUTS) affect from 75-80% of men undergoing radiation therapy (RT) for prostate cancer. The purpose of this study was to determine the feasibility, safety and efficacy of inexpensive, non-toxic herbal supplement, Saw Palmetto (SP), in treating these distressing symptoms.

The study consisted of two phases: Dose Finding phase (DFP), and Exploratory Randomized Controlled Trail (RCT) phase. In the 12 week DFP, participants were given one of three doses (SP 320 mg, SP 640mg, and SP 960 mg) using the Time-to-Event Continual Reassessment Method to determine the maximum therapeutic dose (MTD). Once the MTD was determined the RCT phase was begun, participants were allocated to receive either the predetermined MTD (960 mg) in the DFP or a placebo to obtain preliminary evidence of efficacy of SP on LUTS.

Safety data consisted of the Common Terminology for Adverse Events criteria for nausea, gastritis, and anorexia. Efficacy of the MTD was evaluated by weekly symptom data and voiding diary. A pill diary was used to ensure the intervention fidelity.

Daktyle

Ostatnia weryfikacja: 08/31/2019
Pierwsze przesłane: 04/22/2012
Szacowana liczba przesłanych rejestracji: 04/22/2012
Wysłany pierwszy: 04/24/2012
Ostatnia aktualizacja przesłana: 09/25/2019
Ostatnia opublikowana aktualizacja: 09/29/2019
Data pierwszego przesłania wyników: 05/03/2016
Data pierwszego przesłania wyników kontroli jakości: 06/15/2017
Data opublikowania pierwszych wyników: 07/13/2017
Rzeczywista data rozpoczęcia badania: 09/30/2011
Szacowana data zakończenia podstawowej działalności: 03/31/2015
Szacowana data zakończenia badania: 03/31/2015

Stan lub choroba

Prostate Cancer

Interwencja / leczenie

Drug: Saw Palmetto

Drug: Phase 2: RCT phase- Placebo

Faza

Faza 1/Faza 2

Grupy ramion

RamięInterwencja / leczenie
Other: Phase 1: The dose finding phase (DFP)
Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
Active Comparator: Phase 2: RCT phase- Saw Palmetto
Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
Placebo Comparator: Phase 2: RCT phase- Placebo
Patients received Soybean Oil Soft Gel as the placebo treatment
Drug: Phase 2: RCT phase- Placebo
placebo (soybean oil soft gel)

Kryteria kwalifikacji

Wiek kwalifikujący się do nauki 21 Years Do 21 Years
Płeć kwalifikująca się do naukiMale
Przyjmuje zdrowych wolontariuszytak
Kryteria

Inclusion Criteria:

- Age 21 years or older

- Adenocarcinoma of the prostate

- Serum Prostate Specific Antigent (PSA) ≤ 40ng/ml

- Combined Gleason Score ≤ 8

- Karnofsky level of performance of > 70%

- Consented to undergo definitive Radiation Therapy

Exclusion Criteria:

- Stage T4 or M1

- Patient using own supply of Saw Palmetto or any other supplement containing the following herbs: Pygeum (African Plum), Urtica Dioica (Stinging nettle), Cucurbita peponis (pumpkin seed), PC-SPES (combination of 8 herbs), Beta-sitsterol (plant sterols) or Cernilton (rye grass pollen).

- Prior pelvic radiation therapy

- Abnormality in liver and kidney function as evidenced by greater than twice the normal values of Blood Urea Nitrogen (BUN), serum creatine, serum transaminases, and alkaline phosphatase.

- Uncontrolled hypertension despite use of antihypertensive medication

- Presence of major psychiatric or medical illness (e.g., major cardiovascular events within the previous 12 months)

Wynik

Podstawowe miary wyników

1. Feasibility [Baseline to Week 12 for each phase.]

Assess a Saw Palmetto supplementation protocol for feasibility by evaluation if at least 70% of eligible men consent, and if at least 70% of men enrolled at each dose complete the study.

2. Efficacy [HRQOL: Baseline, week 12, 14, & 22. IPSS: Baseline, week 3-12, 14, & 22.]

Evaluate preliminary efficacy of Saw Palmetto at the MTD as compared to the placebo group with respect to Health-Related Quality of life (HRQOL) including physical functioning and symptoms. The outcomes were measured using 1) the International Prostate Symptoms Score (IPSS) and 2) the total and subscales of the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The IPSS which ranges from 0-35. A lower score indicates better symptoms. The FACT-P has the following subscores and ranges: emotional well-being (0-24), functional well-being (0-28), physical well-being (0-28), social well-being (0-28), and prostate-specific concerns (0-48). The FACT-P total is comprised of the sum of the subscales and ranges from 0-156. For the FACT-P, a higher score indicates better quality of life. Each values was created as an average over time from a linear mixed effects model that adjusted for baseline values.

3. Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose [Baseline to Week 12]

Dose limiting toxicities was defined as the Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher for gastrointestinal symptoms (nausea, gastritis, anorexia). The maximum tolerated dose (MTD) was established among 320mg, 640mg,or 960mg, at which less than 10% of men report less than a grade 2 of gastrointestinal symptoms.

Dołącz do naszej strony
na Facebooku

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo

  • Działa w 55 językach
  • Ziołowe leki poparte nauką
  • Rozpoznawanie ziół na podstawie obrazu
  • Interaktywna mapa GPS - oznacz zioła na miejscu (wkrótce)
  • Przeczytaj publikacje naukowe związane z Twoim wyszukiwaniem
  • Szukaj ziół leczniczych po ich działaniu
  • Uporządkuj swoje zainteresowania i bądź na bieżąco z nowościami, badaniami klinicznymi i patentami

Wpisz objaw lub chorobę i przeczytaj o ziołach, które mogą pomóc, wpisz zioło i zobacz choroby i objawy, na które są stosowane.
* Wszystkie informacje oparte są na opublikowanych badaniach naukowych

Google Play badgeApp Store badge